Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

BACKGROUND: Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)–positive...

詳細記述

保存先:
書誌詳細
出版年:N Engl J Med
主要な著者: von Minckwitz, Gunter, Procter, Marion, de Azambuja, Evandro, Zardavas, Dimitrios, Benyunes, Mark, Viale, Giuseppe, Suter, Thomas, Arahmani, Amal, Rouchet, Nathalie, Clark, Emma, Knott, Adam, Lang, Istvan, Levy, Christelle, Yardley, Denise A., Bines, Jose, Gelber, Richard D., Piccart, Martine, Baselga, Jose
フォーマット: Artigo
言語:Inglês
出版事項: 2017
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5538020/
https://ncbi.nlm.nih.gov/pubmed/28581356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1703643
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料